Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SOM
vs
S
S&P/ASX 300
SOM
Over the past 12 months, SOM has underperformed S&P/ASX 300, delivering a return of -66% compared to S&P/ASX 300's 4% drop.
Stocks Performance
SOM vs S&P/ASX 300
Performance Gap
SOM vs S&P/ASX 300
Performance By Year
SOM vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Somnomed Ltd
Glance View
SomnoMed makes custom dental devices that help people with obstructive sleep apnea and related snoring problems breathe better at night. Its main product is a mouthguard-like appliance fitted by dentists or sleep clinics, designed to hold the jaw in a position that keeps the airway open. The company is part of the medical and dental supply chain, sitting between clinicians who diagnose sleep disorders and patients who need a non-CPAP treatment option. It sells these oral appliances through dental professionals, sleep physicians, and clinic networks, and it earns money when those devices are prescribed, fitted, and supplied to patients. SomnoMed also supports the treatment process with training, patient care tools, and services that help clinicians choose and manage the right device. Its customers are mainly dentists, sleep clinics, doctors, and the patients they treat. What makes the business distinct is that it focuses on a specific, non-surgical treatment path for sleep apnea rather than broad medical equipment. The company depends on clinical adoption, reimbursement rules, and the willingness of doctors and dentists to use oral appliances as an alternative to machines or surgery. That gives it a niche role in sleep medicine and dental care, with demand tied to how widely these devices are accepted as a standard treatment option.